DelveInsight’s, “Neuroendocrine Tumors Pipeline Insight, 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Neuroendocrine Tumors pipeline landscape. It covers the Neuroendocrine Tumor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuroendocrine Tumor pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Neuroendocrine Tumors Pipeline. Dive into DelveInsight’s comprehensive report today! @ Neuroendocrine Tumors Pipeline Outlook

Key Takeaways from the Neuroendocrine Tumors Pipeline Report

• On 11 August 2025, Boehringer Ingelheim announced a study is to find a suitable dose of BI 764532 that people with advanced cancer can tolerate. 2 different doses of BI 764532 are tested in this study. Another purpose is to check whether BI 764532 can make tumours shrink. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer.
• On 06 August 2025, Advanced Accelerator Applications conducted a study consisted of a screening phase, a treatment phase, an optional cross-over phase for subjects assigned to the control arm, optional re-treatment phase for subjects assigned to the Lutathera arm, and a follow-up phase. This study compared treatment with Lutathera (7.4 GBq/200 mCi 4 × administrations every 8 weeks ± 1 week; cumulative dose: 29.6 GBq/800mCi) plus octreotide long-acting release (LAR) (30 mg every 8 weeks during Lutathera treatment and every 4 weeks after last Lutathera treatment) and high dose octreotide LAR (60 mg every 4 weeks).
• DelveInsight’s Neuroendocrine Tumors pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Neuroendocrine Tumors treatment.
• The leading Neuroendocrine Tumors Companies such as Camurus, Vyriad, Inc., TYK Medicines, Orano Med, Advanced Accelerator Applications, Sinotau Pharmaceutical Group, ITM Solucin GmbH, Molecular Targeting Technologies, Inc., Biotheus Inc., Aadi Bioscience, Inc., TaiRx, Inc. and others.
• Promising Neuroendocrine Tumors Pipeline Therapies such as lanreotide acetate, Lanreotide (Autogel formulation) and Temozolomide, AlphaMedix, Octreotide LAR, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Neuroendocrine Tumors Treatment Drugs

Neuroendocrine Tumors Emerging Drugs Profile

• CAM2029: Camurus

CAM2029 is a long-acting subcutaneous depot of octreotide under development for the treatment of three rare diseases: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET) and polycystic liver disease (PLD). Studies completed to date demonstrate that CAM2029 has the potential to provide significantly higher octreotide bioavailability and octreotide exposure with the potential for improved treatment efficacy, compared to current market leading products. CAM2029 is designed to enable easy self-administration, including the option of a pre-filled pen device. Currently, the drug is in the Phase III stage of its development for the treatment of gastroentero pancreatic neuroendocrine tumors.

• AlphaMedix: Orano Med

AlphaMedix is a somatostatin receptor targeting peptide radiolabeled with 212Pb. Somatostatin receptors are overexpressed in most neuroendocrine tumors, a heterogeneous group of rare neoplasms that originate from neuroendocrine cells. These neoplasms occur mostly in the gastrointestinal tract and pancreas, but can also occur in other tissues including thymus, lung, and other uncommon sites such as ovaries, heart, and prostate. After the promising results of the Phase I clinical trial launched early 2018, a Phase II was initiated late 2021 to assess the efficacy of Alphamedix in the treatment of neuroendocrine tumors. The study is currently recruiting patients in the US. Currently the drug is in Phase II stage of its clinical development.

• Voyager-V1: Vyriad, Inc.

VSV-IFNβ-NIS (Voyager V1; VV1) is derived from VSV, a bullet-shaped, negative-sense RNA virus with low human seroprevalence; it is engineered to replicate selectively in and kill human cancer cells. VV1 encodes hIFNβ to increase antitumoral immune response and tumor specificity, plus the thyroidal sodium iodide symporter NIS to allow imaging of virus. VV1 is synergistic with different anti-PD-(L)1 antibodies in several tumor models. Currently the drug is in Phase I/II stage of its development.

The Neuroendocrine Tumors Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Neuroendocrine Tumors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroendocrine Tumors Treatment.
• Neuroendocrine Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Neuroendocrine Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuroendocrine Tumors market

Explore groundbreaking therapies and clinical trials in the Neuroendocrine Tumors Pipeline. Access DelveInsight’s detailed report now! @ New Neuroendocrine Tumors Drugs

Neuroendocrine Tumors Companies

Camurus, Vyriad, Inc., TYK Medicines, Orano Med, Advanced Accelerator Applications, Sinotau Pharmaceutical Group, ITM Solucin GmbH, Molecular Targeting Technologies, Inc., Biotheus Inc., Aadi Bioscience, Inc., TaiRx, Inc. and others.

Neuroendocrine tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Neuroendocrine Tumors Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Neuroendocrine Tumors Market Drivers and Barriers

Scope of the Neuroendocrine Tumors Pipeline Report

• Coverage- Global
• Neuroendocrine Tumors Companies- Camurus, Vyriad, Inc., TYK Medicines, Orano Med, Advanced Accelerator Applications, Sinotau Pharmaceutical Group, ITM Solucin GmbH, Molecular Targeting Technologies, Inc., Biotheus Inc., Aadi Bioscience, Inc., TaiRx, Inc., and others.
• Neuroendocrine Tumors Pipeline Therapies- lanreotide acetate, Lanreotide (Autogel formulation) and Temozolomide, AlphaMedix, Octreotide LAR, and others.
• Neuroendocrine Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Neuroendocrine Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth pipeline report today! @ Neuroendocrine Tumors Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Neuroendocrine Tumors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Neuroendocrine Tumors– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. RYZ101: RayzeBio, Inc.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Ramucirumab: Eli Lilly and Company
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ADCT-701: ADC Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Neuroendocrine Tumors Key Companies
21. Neuroendocrine Tumors Key Products
22. Neuroendocrine Tumors- Unmet Needs
23. Neuroendocrine Tumors- Market Drivers and Barriers
24. Neuroendocrine Tumors- Future Perspectives and Conclusion
25. Neuroendocrine Tumors Analyst Views
26. Neuroendocrine Tumors Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight